1100/10/190

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it contains a valid OMB control number

Complete if Known

Application Number	10/594,420	Ī
Filing Date	May 18, 2005	
First Named Inventor	SUN	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	_
Attorney Docket Number	17357.01701US	_

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT (Use as many sheets as neessary)

/Sahar Javanmard/

of 8

Substitute for form 1449/PTO

Examiner Signature

Translation is attached.

Sheet 1 U. S. PATENT DOCUMENTS Name of Patentee or Cite No.1 Document Number estion Date Page Columns Lines Where MM-DD-YYYY Relevant Pesseges or Relevant Initials\* Applicant of Cited Document Number-Kind Code<sup>2</sup> (F Arrown) US- 4.560,774 12-24-1985 Pettit et al. US- 4.833,257 05-23-1989 Pettit et al. US- 5.072.004 12-10-1991 Pettit US-5,196,447 03-23-1993 Pettit et al <sup>US-</sup> 5,288,514 02-22-1994 Ellman US- 5.359,115 10-25-1994 Campbell et al. US- 5,362,899 11-08-1994 Campbell US- 5,393,897 Pettit et al. 02-28-1995 US- 5,625,232 04-29-1997 Numata et al. US- 5,891,870 04-06-1999 Driedger et al US- 5,891,906 Driedger et al. 04-06-1999 <sup>US-</sup> 5,955,501 09-21-1999 Driedger et al. <sup>US-</sup> 5,962,498 10-05-1999 Driedger et al. US- 5.962.504 10-05-1999 Kozikowski et al. US- 6,043,270 03-28-2000 Driedger et al. US- 6,080,784 06-27-2000 Driedger et al. US- 6 187 568 BI 02-13-2001 Nishida et al. US- 2003/017385 A1 09-11-2003 Alkon et al.

Examiner Initiels*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Nama of Patantea or Applicant of Cited Document	Pages, Columns, Lines, Whera Relavant Passages Or Relevent Figures Appear	٠,٠
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MINI-DO-TTTT		Of Nelevent Figures Appear	Ľ
		WO 91/07087	05-30-1991	Affymax Technologies, N.V.		
		WO 92/10092	06-25-1992	Affymax Technologies, N.V.		
		WO 93/20242	10-14-1993	The Scripps Research Inst.		L
		WO 93/09668	05-27-1993	Affymax Technologies, N.V		
		WO 94/08051	04-14-1994	The Trustlees of Columbia Univ.		
	Г	WO 02/097423 A3	11-07-2002	BRNI		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of
USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For
Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by
the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Intersusion is stancinou.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (end by the USFTO to process) an application. Confidentiality is governed by 38 USC, 122 and 37 CFR 1.4. This collection is estimated to take 2 hours so complete. The collection is estimated to take 2 hours so complete, and confidentiality processing the properties of the total USFTO. Time will wave depending upon the endicidual case, and confidentiality and confidential to the CFR of the confidential case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CFR officiality of the confidency of TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1459.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

00/04/0011

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains e valid OMB control number.

Complete if Known

Substitute for form 1449/PTO Application Number

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as ncessary) of 8

/Sahar Javanmard/

Sheet 2

10/594.420 Filing Date May 18, 2005 First Named Inventor Art Unit Not Yet Assigned Not Yet Assigned Evaminer Name Attorney Docket Number 17357.01701US

Exeminer	Cite No.1	Document Number	Publication Date	Neme of Patentee or	Peges, Columns, Lines, Where
Initials*	No.1	Number-Kind Code <sup>2 (f Anount)</sup>	Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	
		US-			·
		US-			
		US-			
		US-			
		US-	1		
		US-			
		US-			
		US-	†		<u> </u>
		US-			
		US-			1
		US-			
	<del>                                     </del>	US-	1		

		FOREI	GN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevent Pessages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevent Figures Appear	T <sup>6</sup>
		WO 03/075930 A1	09-18-2003	BRNI		
		WO 98/32464 A!	07-30-1998	Goldshield Pharmacauticals Limited		
						Ш
	_					Ш
	<u> </u>					Щ
L						ш

ч			00/04/2011
		Initial if reference considered, whether or not citation is in conformance with MPEP 609. Dre	
		nclude copy of this form with next communication to applicant. 1 Applicant's unique citation di	
		nt Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document,	
		tent documents, the indication of the year of the reign of the Emperor must precede the serial ne	
	the appropria	te symbols es indicated on the document under WIPO Standard ST.16 if possible.   Applicar	it is to place a check mark here if English language

Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) en application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USP1 to process) on appointant. Confidentiatily is governed by 30 USC 172 and 37 CPR 1.14. This collection is estimated to take 2 Darus to complete, including galietine; preparing, and submitting the completed application from the thic USP1.0 Time will wave depending upon the individual case. Any comments on the emount of time you require to complete this from and/or suggestions for reducing this burden, should be sent to the Chel riformation Officer, U.S. Patent and Trademark Cinic, P.O. Bost 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, P.O. Box 1450, Assandis, N.2 231-1450. D. NOT IS RENOT PRES DOT COMPLETED FORMS TO THIS ADDRESS. SEND TO. COMPLETE THE PRESENCE FORMS TO THIS ADDRESS. SEND TO. COMPLETE THE PRESENCE FORMS TO THIS ADDRESS. SEND TO. COMPLETE THE PRESENCE FOR THE PRESENCE FORMS TO THIS ADDRESS. SEND TO THE PRESENCE FOR THE PRESENCE FOR THIS ADDRESS. SEND TO THE PRESENCE FOR THE PRESENCE

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO	e required to respond to a collection	of information unless it contains a velid OMB control number.  Complete if Known
A SASSANATO TO THE SASSANATO TO SASSANATO TA	Application Number	10/594,420
INFORMATION DISCLOSURE	Filing Date	May 18, 2005
STATEMENT BY APPLICANT	First Named Inventor	SUN
(Usa as many sheets as necessary)	Art Unit	Not Yet Assigned
(Out as many should as nocessary)	Examiner Name	Not Yet Assigned
Sheet 3 of 8	Attorney Docket Number	17357.01701US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Sun et al., "Carbonic anhydrase gating of attention: memory therapy and enhancement," TRENDS in Pharmacological Sciences, Vol. 23, No. 2, February 2002	
		Sun et al., "Functional switching of GABAergic synapses by ryanodine receptor activation," Proc. Nat'l. Acad. Sci USA, 97: 12300-12305, 2000	
		Battaini, "Protein Kinase C Isoforms as Therapeutic Targets in Nervous System Disease States," Pharmacological Research, Vol. 44, No. 5, 2001	
		Coull et al., "Altered brain protein kinase C in depression: a post-mortem study," European Neuropsychopharmacology 10 (2000) 283-288	
		Manji et al., "Post-receptor Signaling Pathways in the Pathophysiology and Treatment of Mood Disorders," Mood Disorders, pp 481-489	
		Bouron et al., "Acute Application of the Tricyclic Antidepressant Desipramine Presynaptically Stimulates the Exceytosis of Glutamate in the Hippocampus, Neuroscience, Vol. 90, No. 3, pp. 729-736, 1999	
		Budziszewska et al., "Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism," British Journal of Phamacology, (2000) 130, 1385-1393	
		Morishita et al., "Effects of tricylic antidepressants on protein kinase C activity in rabbit and human platelets in vivo," Journal of Affective Disorders 70 (2002) 329-332	
		Casini et al., "Carbonic Anhydrase Activators. The Selective Serotonin Reuptake Inhibitors Fluoxetine, Sertraline and Citalopram Are Strong Activators of Isozymes I and II," Bioorganic & Medicinal Chemistry Letters 13 (2003) 2765-2768	
		Wang et al., "Flouxetine Depresses Glutamate Exocylosis in the Rat Cerebrocortical Nerve Terminals (Synaptosomes) via Inhibition of P/Q Ca2+ Channels." SYNAPSE 48:170-177 (2003)	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>ExAMMSR\*: Initial infetier new considered, whether or not classion is a conformance with MPEP 600. Draw his through classion in on conformance and not a conformance with MPEP 600. Draw his through classion in on in conformance with MPEP 600. Draw his through classic many classic designation conformation is required to state or required to obtain or retain a banest for the public which is to file (and by the USPTO or process) an application. Confidentiality is governed by 3 USC 1.72 and 3 C78T 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 3 USC 1.72 and 3 C78T 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 3 USC 1.72 and 3 C78T 1.14. This collection is estimated to take 2 hours to complete, including the amount of time you require to complete this form and/or suggestions for reducing this busides, should be sent to the Christ Information Circle. US. Patent and Trademshot Office, 9.0. Bot 1560, Ascardio, VA V.2313-1450, D.O. NOT SSHOT, PEES OR COMPLETED FORMS TO THIS ADDRESS. SENTO TIS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unities; in certains a wide IOMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/594,420 INFORMATION DISCLOSURE Filing Date May 18, 2005 STATEMENT BY APPLICANT First Named Inventor SUN Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number Sheet 4 of 8 17357.01701US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, orly and/or country where published.	T²
		Gould et al., "Signaling networks in the pathophysiology and treatment of mood disorders," Journal of Psychosomatic Research 53 (2002) 687-697	
		Abramets et al., "Behavioral Depression-Related Modifications of the Properties of Glutamatergic Synapses in the Basolateral Amygdalar Nucleus in Rats," Neurophysiology, Vol. 34, No. 4, 2002	
,		Shelton, "Cellular Mechanisms in the Vulnerability to Depression and Response to Antidepressants," DEPRESSION, Vol. 23, No. 4, December 2000	
		Popoli et al., "Second Messenger-Regulated Protein Kinases in the Brain: Their Functional Role and the Action of Antidepressant Drugs," J. Neurochem., Vol. 74, No. 1, 2000	
		Johnston-Wilson et al., "Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder," Molecular Psychiatry (2000) 5, 142-149	
		Morishita et al., "Different effect of desipramine on protein kinase C in platelets between bipolar and major depressive disorders," Psychiatry and Clinical Neurosciences (1999), 53, 11-15	
		Lieb et al., "Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor," Journal of Neurochemistry, 2003, 86, 69-76	
		Suzuki et al., "Altered 5-HT-Induced Calcium Response in the Presence of Staurosporine in Blood Platelets from Bipolar Disorder Patients," Neuropsychopharmacology (2003) 28, 1210-1214	
		Hayes, "Acetozolamide in Bipolar Affective Disorders," Annals of Clinical Psychiatry, Vol. 6, No. 2, 1994	
		Lenox et al., "Lithium and the Brain: A Psychopharmacological Strategy to a Molecular Basis for Manic Depressive Illness," Clin. Chem. 40/2, 309-314 (1994)	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include Copy or the form with next communication to appeared.

A pipicart's surface challend edeplication tumble (optional). A popicart is not please inches may be represented to the challenge of the control of the challenge of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. OEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/594.420 INFORMATION DISCLOSURE Filing Date May 18, 2005 STATEMENT BY APPLICANT First Named Inventor SUN Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number Sheet 5 of 8 17357.01701US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Wang et al., "Increased membrane-associated protein kinase C activity and translocation in blood plateiets from bipolar affective disorder patients," Journal of Psychiatric Research 33 (1999) 171-179	
		Manji et al., "Protein Kinace C Signaling in the Brain: Molecular Transduction of Mood Stabilization in the Treatment of Manic-Depressive Illness," Biol Psychiatry 1999; 46:1328-1351	
		Pandey et al., "Protein Kinase C and Phospholipase C Activity and Expression of Their Specific Isozymes is Decreased and Expression of MARCKS is Increased in Platelets of Bipolar but Not in Unipolar Patients, "Neuropschoparmacology, 2002, Vol. 26, No. 2	
		Yildiz, "Phosphoinositide metabolism, lithium and manic depresive illness," Spectroscopy 16 (2002) 307-316	
		Barbas et al., "Multiple Serotonergic Mechanisms Contributing to Sensitization in Aplysia: Evidence of Diverse Serotonin Receptor Subtypes," Serotonin & Memory, pp. 373-386	
		Pandey et al., "Protein Kinace C in Platelets of Depressed Patients," Biol Psychiatry 1998; 44:909-911	
		Besag, "Behavioral Effects of the New Anticonvulsants," Drug Safety 2001: 24(7) 513-536	
		Hahn et al., "Abnormalities in protein kinase C signaling and the pathphysiology of bipolar disorder," Bipolar Disorders 1999: 2: 81-86	
		International Search Report for PCT/US2005/017158 dated December 14, 2006	
		Mannisto, P.T. et al., "Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression", European Journal of Pharmacolow 274 (1998) 229-233	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011

considered. Include copy of this form with next communication to applicant.

Consideration, inclined copy in the form with mark commitmentation to applicate in In Applicant is unique collection designation munities (optional 2.4 Applicants in large sea check, mark here if English Inspuse). Franction is statistiched.

1. Applicants in value obtained to applicate the properties of the properti Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

17357.01701US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449/PTO Application Number 10/594.420 INFORMATION DISCLOSURE Filing Date May 18, 2005 STATEMENT BY APPLICANT First Named Inventor SUN Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned

Attorney Docket Number

Sheet 6

of 8

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner. Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kravitz, H.M. et al., "Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders", Journal of the American Osteopathic Associate 1984 United states, Vol. 84, No. 1 Suppl., 1984, pp. 119-123, XP008057181	
		Chetkovich, D.M., et al., "N-Methyl-D-aspartate receptor activation increases cAMP levels and voltage-gated Ca2+ channel activity in area CA1 of hippocampus", Proc. Natl. Acad. Sci. USA Vol. 88. Do. 8467-8471. August 199	
		C-T Hu, Mickey, et al., "Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11", Oncogene (1999) 18, 2635-2642	
		C-T Hu, Mickey, et al., FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation", Mollecular and Cellular Biology, Oct. 1998, p. 8083-8074	
		Mody, Monica, et al., "Genome-wide gene expression profiles of the developing mouse hippocampus", PNAS, July 27, 2001, Vol. 98, No. 14, p. 8862-8867	
		Cavallaro, Sebastiano, et al., "Late memory-related genes in the hippocampus revealed by RNA fingerprinting", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 9669-9673, September 1997	
		Tsien, Joe Z., et al., "The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory", Cell, Vol. 87, 1327-1338, December 27, 1996	
		Ohbayashi, Norihiko, et al., "Structure and Expression of the mRNA Encoding a Novel Fibroblast Growth Factor, FGF-18", The Journal of Biological Chemistry, Vol. 273, No. 29, Issue of July 17, no. 1846;148164 1999.	
		Calo, Girolamo, et al., "Pharmacology of nociceptin and its receptor: a novel therapeutic target", British Journal of Pharmacology (2000) 129, 1261-1283	
		Gomez, Marie, et al., "Ca2+ Signaling via the Neuronal Calcium Sensor-1 Regulates Associative Learning and Memory in C. elegans", Neuron, Vol. 30, 241-248, April 2001	

Examiner					П	D	ate			Т	_	08	04/2	2011		٦
Signature	/Sahar Javanmard/			 	 _	C	onsid	erec	1							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

1 Applicants unique clation designation number (optional). 2 Applicant is to place a check mark here if English language Transition is attached.

This collection of information is required by 37 CFR 19.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.1.4. This collection is estimated to take 2 hours to complete, including a distribution of the completed application from the to USPTO. Time will very depending upon the individual case. An expenditure of the completed application from the four USPTO. Time will very depending upon the individual case. As you will be used to the complete application from the four the complete application from the USPTO. The will very depending upon the individual case. As you will be used to the complete application of the USPTO o

PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
GLIGATION 144511 10	Application Number	10/594,420			
INFORMATION DISCLOSURE	Filing Date	May 18, 2005			
STATEMENT BY APPLICANT	First Named Inventor	SUN			
(Use as many sheets as necessary)	Art Unit	Not Yet Assigned			
(see as many anders as naces any)	Examiner Name	Not Yet Assigned			
Sheet 7 of 8	Attorney Docket Number	17357.01701US			

F	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	_
Examiner Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Masson, J., et al., "Neurotransmitter Transporters in the Central Nervous System", Pharmacological Reviews, Vol. 51, No. 3	
		Katzoff, Ayelet, et al., "Nitric Oxide Is Necessary for Multiple Memory Processes after Learning That a Food Is Inedible in Aplysia", The Journal of Neurosciences, November 1, 2002, 22(21): 9581-9594	
		Kornhauser, Jon M., et al., "A Kinase to Remember: Dual Roles for MAP Kinase in Long-Term Memory", Neuron Vol. 18, 839-842, June, 1997	
		Impey, Soren, et al., "Making New Connections: Role of ERK/MAP Kinase Signaling in Neuronal Plasticity", Neuron, Vol. 23, 11-14, May, 1999	
		Zhen, Xuechu, et al., "The p38 Mitogen-Activated Protein Kinase Is Involved in Associative Learning in Rabbits", The Journal of Neuroscience, August 1, 2001, 2(15):5513-5519	
		Davis, Roger J., "The Mitogen-activated Protein Kinase Signal Transduction Pathway", The Journal of Biological Chemistry, Vol. 268, No. 20, Issue of July 15 pp. 14553-14556, 1993	
		Berman, Diego E., et al., "Specific and Differential Activation of Mitogen-Activated Protein Kinase Cascades by Unfamiliar Taste in the Insular Cortex of the Behaving Rat", The Journal of Neuroscience, December 1, 1998, 18(23):1003-10044	
		Zhang, Wandong, et al., "Citron Binds to PSD-95 at Glutamatergic Synapses on Inhibitory Neurons in the Hippocampus", The Journal of Neuroscience, January 1, 1999, 19 (1/196-108	
		Kosik, Kenneth S., et al., "Microtubule-associated protein 2: Monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzhelmer neurofibrillary tangles", Proc. Natl. Acad. Sci. USA, Vol. 18, pp. 7941-7945, December 1984	
		Yamanouchi, Hideo, et al., "Early forms of microtubule-associated protein are strongly expressed in cortical dysplasia", Acta Neuropathol (1998) 95:466-470	

Examiner		Date	08/04/2011
Signature	/Sahar Jayanmard/	Considered	00/04/2011

\*EXAMINER: Initial if reference considered, whether or not citation is in confoconsidered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique classified designation number (optional). Applicant is not place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.85. This information is required to obtain or retain a benefit by the public which is to like (and by the USPTO This collection of information is required by 37 CFR 1.85. This information is required to obtain or retain a benefit by the public which is to like (and by the USPTO This collection) and obtaining the completed application from the to USPTO. Time will way depending upon the individual case. An exementary of the amount of time you require to complete this forming from and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, V.A. 22313-1450, D.O. NOT SENDE PEES OR COMPLETED FORMSTO THIS ADDRESS. SENDER. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (09-05)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/594,420		
			CLOSURE	Filing Date	May 18, 2005		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	SUN		
	(Use as many she	ate ae n	ecessand	Art Unit	Not Yet Assigned		
	(ooo aa many ano	010 20 77	occooury)	Examiner Name	Not Yet Assigned		
Sheet	8	of	8	Attorney Docket Number	17357.01701US		

Examiner	Cita	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	Cite No.1	include name of the author (in CAPTIAL LETTENS), title of the article (when appropriate), title of the item (book, magazine, journal, senial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Woolf, Nancy J., et al., "Hippocampal microtubule-associated protein-2 alterations with contextual memroy", Brain Research, March 6, 1999, 821(1):241-249	
		Berke, Joshua, et al., "Dopamine and Glutamate Induce Distinct Striatal Splice Forms of Ania-6, an RNA Polymerase II-Associated Cyclin", Neuron, Vol. 32, 277-287, October 25, 2001	
		Tischmeyer, W., et al., "Activation of immediate early genes and memory formation", CMLS, Cell. Mol. Life Sci. 55 (1999) 564-574	
		·	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011

<sup>&</sup>quot;EXAMINET: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with these communication to applicate.

1.Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retrian a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours 1 completed, including attaching, preparing, and submitting the completed application from the to ESPTO. Time will very depending upon the includicular case. Any comments on the amount of line you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.